176 related articles for article (PubMed ID: 16011042)
1. Behavior of free testosterone in patients with prostate cancer on androgen deprivation therapy.
Morote J; Esquena S; Abascal JM; Trilla E; Cecchini L; Raventós CX; Catalán R; Reventós J
Int J Biol Markers; 2005; 20(2):119-22. PubMed ID: 16011042
[TBL] [Abstract][Full Text] [Related]
2. Behavior of free testosterone in patients with prostate cancer on androgen deprivation therapy.
Morote J; Esquena S; Abascal JM; Trilla E; Cecchini L; Ravents CX; Cataln R; Revents J
Int J Biol Markers; 2005; 20(2):119-222. PubMed ID: 28207137
[TBL] [Abstract][Full Text] [Related]
3. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
[TBL] [Abstract][Full Text] [Related]
4. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer.
Morote J; Esquena S; Abascal JM; Trilla E; Cecchini L; Raventós CX; Catalán R; Reventós J
Urol Int; 2006; 77(2):135-8. PubMed ID: 16888418
[TBL] [Abstract][Full Text] [Related]
5. Testosterone Recovery Profiles After Cessation of Androgen Deprivation Therapy for Prostate Cancer.
Nascimento B; Miranda EP; Jenkins LC; Benfante N; Schofield EA; Mulhall JP
J Sex Med; 2019 Jun; 16(6):872-879. PubMed ID: 31080102
[TBL] [Abstract][Full Text] [Related]
6. Effect of androgen deprivation therapy in the thyroid function test of patients with prostate cancer.
Morote J; Esquena S; Orsola A; Salvador C; Trilla E; Cecchini L; Raventós CX; Planas J; Catalán R; Reventós J
Anticancer Drugs; 2005 Sep; 16(8):863-6. PubMed ID: 16096434
[TBL] [Abstract][Full Text] [Related]
7. Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy.
Morote J; Planas J; Salvador C; Raventós CX; Catalán R; Reventós J
BJU Int; 2009 Feb; 103(3):332-5; discussion 335. PubMed ID: 19007366
[TBL] [Abstract][Full Text] [Related]
8. Hormonal response recovery after long-term androgen deprivation therapy in patients with prostate cancer.
Planas J; Celma A; Placer J; Cuadras M; Regis L; Gasanz C; Trilla E; Salvador C; Lorente D; Morote J
Scand J Urol; 2016 Dec; 50(6):425-428. PubMed ID: 27628623
[TBL] [Abstract][Full Text] [Related]
9. Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients.
Wang Y; Dai B; Ye DW
Asian J Androl; 2017; 19(2):178-183. PubMed ID: 26975487
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the lipid profile and atherogenic risk during androgen deprivation therapy in prostate cancer patients.
Salvador C; Planas J; Agreda F; Placer J; Trilla E; Lopez MA; Morote J
Urol Int; 2013; 90(1):41-4. PubMed ID: 23235105
[TBL] [Abstract][Full Text] [Related]
11. Quality of life in prostate cancer patients taking androgen deprivation therapy.
Dacal K; Sereika SM; Greenspan SL
J Am Geriatr Soc; 2006 Jan; 54(1):85-90. PubMed ID: 16420202
[TBL] [Abstract][Full Text] [Related]
12. Study of testosterone-guided androgen deprivation therapy in management of prostate cancer.
Niraula S; Templeton AJ; Vera-Badillo FE; Joshua AM; Sridhar SS; Cheung PW; Yip PM; Dodd A; Nugent Z; Tannock IF
Prostate; 2016 Feb; 76(2):235-42. PubMed ID: 26768279
[TBL] [Abstract][Full Text] [Related]
13. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
[TBL] [Abstract][Full Text] [Related]
14. The Association of A Number of Risk Factors With Depression in Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy.
Kim CH; Kim KT; Oh JK; Chung KJ; Kim TB; Jung H; Yoon SJ; Kim KH
Urol J; 2018 May; 15(3):104-108. PubMed ID: 29388185
[TBL] [Abstract][Full Text] [Related]
15. Free Testosterone During Androgen Deprivation Therapy Predicts Castration-Resistant Progression Better Than Total Testosterone.
Regis L; Planas J; Carles J; Maldonado X; Comas I; Ferrer R; Morote J
Prostate; 2017 Jan; 77(1):114-120. PubMed ID: 27800640
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Impact of Serum Testosterone and Body Mass Index Before Androgen-deprivation Therapy in Metastatic Prostate Cancer.
Shiota M; Takeuchi A; Sugimoto M; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Yokomizo A
Anticancer Res; 2015 Dec; 35(12):6925-32. PubMed ID: 26637918
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with testosterone recovery after androgen deprivation therapy in patients with prostate cancer.
Nam W; Choi SY; Yoo SJ; Ryu J; Lee J; Kyung YS; Han JH; You D; Jeong IG; Hong JH; Ahn H; Kim CS
Investig Clin Urol; 2018 Jan; 59(1):18-24. PubMed ID: 29333510
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
19. Serum testosterone levels after medical or surgical androgen deprivation: a comprehensive review of the literature.
Nishiyama T
Urol Oncol; 2014 Jan; 32(1):38.e17-28. PubMed ID: 23769268
[TBL] [Abstract][Full Text] [Related]
20. The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism.
Shiota M; Fujimoto N; Yokomizo A; Takeuchi A; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Eto M
Prostate Cancer Prostatic Dis; 2016 Jun; 19(2):191-6. PubMed ID: 26857022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
